BACKGROUND: T-cell responses against dormancy-, resuscitation-, and reactivation-associated antigens of Mycobacterium tuberculosis are candidate biomarkers of latent infection in humans. METHODOLOGY/PRINCIPAL FINDINGS: We established an assay based on two rounds of in vitro restimulation and intracellular cytokine analysis that detects T-cell responses to antigens expressed during latent M. tuberculosis infection. Comparison between active pulmonary tuberculosis (TB) patients and healthy latently M. tuberculosis-infected donors (LTBI) revealed significantly higher T-cell responses against 7 of 35 tested M. tuberculosis latency-associated antigens in LTBI. Notably, T cells specific for Rv3407 were exclusively detected in LTBI but not in TB patients. The T-cell IFNgamma response against Rv3407 in individual donors was the most influential factor in discrimination analysis that classified TB patients and LTBI with 83% accuracy using cross-validation. Rv3407 peptide pool stimulations revealed distinct candidate epitopes in four LTBI. CONCLUSIONS: Our findings further support the hypothesis that the latency-associated antigens can be exploited as biomarkers for LTBI.
BACKGROUND: T-cell responses against dormancy-, resuscitation-, and reactivation-associated antigens of Mycobacterium tuberculosis are candidate biomarkers of latent infection in humans. METHODOLOGY/PRINCIPAL FINDINGS: We established an assay based on two rounds of in vitro restimulation and intracellular cytokine analysis that detects T-cell responses to antigens expressed during latent M. tuberculosis infection. Comparison between active pulmonary tuberculosis (TB) patients and healthy latently M. tuberculosis-infected donors (LTBI) revealed significantly higher T-cell responses against 7 of 35 tested M. tuberculosis latency-associated antigens in LTBI. Notably, T cells specific for Rv3407 were exclusively detected in LTBI but not in TBpatients. The T-cell IFNgamma response against Rv3407 in individual donors was the most influential factor in discrimination analysis that classified TBpatients and LTBI with 83% accuracy using cross-validation. Rv3407 peptide pool stimulations revealed distinct candidate epitopes in four LTBI. CONCLUSIONS: Our findings further support the hypothesis that the latency-associated antigens can be exploited as biomarkers for LTBI.
In the vast majority of individuals, specific cellular immunity against M. tuberculosis is capable of controlling infection leading to latent M. tuberculosis infection (LTBI) [1]. LTBI is thought to be associated with a dormancy/non-replicating state of low metabolic activity of the pathogen. Dormancy-related (DosR) antigens as well as proteins expressed during reactivation and resuscitation of dormant bacilli are candidate biomarkers for LTBI and disease reactivation [2], [3], [4]. A limited number of studies tested latency-associated antigens in immunologic assays. These showed that DosR antigens induced T-cell cytokine expression in humans [5] and mice [6]. Resuscitation-promoting factors (rpf) induced immune responses in mice [7] but have not been tested in humans. Recent studies based on M. tuberculosis knock-out strains revealed that Rv3407, a protein which is not expressed in M. bovis BCG at detectable abundance [8], is under the control of two rpf [9]. Neither Rv3407 nor reactivation-associated antigens (i.e. Rv0104, Rv1115 [10]) have been tested for immunogenicity so far. For reasons of comprehensibility we use the term latency-associated antigens for M. tuberculosis proteins involved in dormancy, resuscitation, and reactivation of M. tuberculosis.We tested the immunogenicity of 35 latency-associated antigens using different assays based on intracellular cytokine staining for IFNγ and IFNγ-ELISA. IFNγ is a crucial mediator of protection against tuberculosis which strongly depends on T helper type-1 immunity. IFNγ activates infected macrophages at the site of bacterial residence - an essential mechanism for the killing of mycobacteria [11]. IFNγ release in response to immunodominant antigens (i.e. ESAT6, CFP10) is used in standard tests for M. tuberculosis infection (IFNγ release assays, IGRA) [12].IGRA as well as standard intracellular cytokine staining methods are based on short-term incubation between 6 and 24 h [13]. Principally short-term assays detect recent M. tuberculosis infection while prolonged in vitro stimulation increases sensitivity for LTBI [14], [15], [16]. Yet, these assays remain insufficient as robust correlates of protection against M. tuberculosis
[17]. Therefore, biomarkers which reliably predict protective immunity are urgently needed [18]. Antigens predominantly expressed by dormant M. tuberculosis during LTBI are promising candidate immune markers of protection [5]. We therefore decided to develop an assay based on two rounds of in vitro restimulation, to determine IFNγ production in response to M. tuberculosis latency-associated antigens in LTBI, TBpatients, and tuberculin skin test (TST)-negative donors. Differentially expressed proteins were then tested for their capacity to discriminate between LTBI and TBpatients. Finally, overlapping peptide pools were applied to identify immunogenic epitopes of the most promising candidate, Rv3407.
Results
Two-rounds of in vitro restimulation detect T-cell responses against latency-associated antigens
We assessed 29 antigens associated with M. tuberculosis dormancy, resuscitation, and reactivation (in short latency, Table 1) for their potential to elicit recall responses after 16 h short-term in vitro stimulation of PBMC from LTBI. We detected IFNγ expression in CD4+CD45RO+ memory T cells from LTBI after stimulation with PPD from M. tuberculosis and, to a minor degree, with M. tuberculosis-immunodominant proteins ESAT6_CFP-10, TB10.4, and Ag85a (figure 1). Notably, none of the latency-associated antigens induced detectable cytokine expression after 16 h in LTBI (figure 1A) and no T-cell responses against M. tuberculosis-specific antigens were detected in 10 tuberculin skin test (TST)-negative donors (data not shown).
Table 1
List of proteins candidates.
Name
Category
ESAT6_CFP-10
Immunodominant M. tuberculosis proteins
TB10.4
Rv3019c
Ag85A
Ag85B
Hsp65
Rv0081
DosR* regulon-encoded M. tuberculosis proteins [2]
Rv0569
Rv0573c
Rv1733c
Rv1734
Rv1735c
Rv1736c
Rv1996
Rv1997_C term
Rv1997_N term
Rv1998
Rv2003
Rv2005c
Rv2006
Rv2032
Rv2623
Rv2624c
Rv2625c
Rv2628
Rv3126c
Rv3129
Rv3133c
Rv0140
M. tuberculosis reactivation-associated proteins [10]
Rv1115
Rv0867c
M. tuberculosis resuscitation promoting factors [30]
Rv1009
Rv1884c
Rv2450c
Rv3407
M. tuberculosis resuscitation-associated protein [19]
M. tuberculosis dormancy-related antigens.
Figure 1
IFNγ-expressing CD4+ CD45RO+ T cells after 16 h and 7 days restimulation with immunodominant and latency-associated antigens from LTBI and TST-negative controls.
Intracellular cytokine expression after 16 h restimulation in PBMC from LTBI (A), and 7 days – including two rounds of in vitro restimulation – in PBMC from LTBI (B, upper graph) and TST-negative donors (B, lower graph) are shown. Scatter plots indicate mean and standard deviation. Percentages of IFNγ-expressing CD4+ CD45RO+ memory T cells are indicated on the y-axis for SEB, PPD from M. tuberculosis, and tested antigens (x-axes). Background values of non-stimulated controls were subtracted for each individual donor. The most promising candidate Rv3407 is underlined. PPD: purified protein derivative of M. tuberculosis; SEB: Staphylococcus enterotoxin B.
IFNγ-expressing CD4+ CD45RO+ T cells after 16 h and 7 days restimulation with immunodominant and latency-associated antigens from LTBI and TST-negative controls.
Intracellular cytokine expression after 16 h restimulation in PBMC from LTBI (A), and 7 days – including two rounds of in vitro restimulation – in PBMC from LTBI (B, upper graph) and TST-negative donors (B, lower graph) are shown. Scatter plots indicate mean and standard deviation. Percentages of IFNγ-expressing CD4+ CD45RO+ memory T cells are indicated on the y-axis for SEB, PPD from M. tuberculosis, and tested antigens (x-axes). Background values of non-stimulated controls were subtracted for each individual donor. The most promising candidate Rv3407 is underlined. PPD: purified protein derivative of M. tuberculosis; SEB: Staphylococcus enterotoxin B.M. tuberculosis dormancy-related antigens.Increased T cell-derived IFNγ responses after prolonged in vitro incubation have been described [5], [14], [16]. Since our own previous experiments indicated that a second stimulation before measurement with the same antigen is optimal for intracellular cytokine detection (data not shown), we combined 7 days of stimulation with restimulation 16 h prior to analysis. Frequencies of IFNγ-expressing T cells in PBMC from LTBI were markedly increased after stimulation with immunodominant proteins or PPD for 7 days (figure 1B, upper graph). In contrast to the short-term single stimulation assay, latency-associated antigens induced IFNγ expression in memory T cells from the majority of LTBI in the long-term restimulation assay (figure 1B, upper graph). Two of these latency-associated antigens, namely Rv0569 and Rv3407, induced IFNγ expression comparable to the ESAT6_CFP-10 fusion protein, the immunodominant antigen which induced the highest frequencies of cytokine-expressing cells in LTBI. In contrast, none of the antigens induced detectable IFNγ expression in T cells from TST-negative donors in this assay (figure 1B, lower graph). Hence, the “7-day two rounds of restimulation” assay detects specific T-cell responses in LTBI which are missed by the 16h short-term assay.Comparisons for the individual donor T-cell responses after 7 days and two rounds of restimulation revealed comparable results against three selected immunodominant antigens (i.e. ESAT6_CFP-10, TB10.4, Ag85A) and three latency-associated antigens (i.e. Rv0569, Rv1734, Rv2003) (data not shown). Considering significantly higher proportions of T cells specific for immunodominant antigens in the short-term assay, a simply ‘boosted’ T-cell response by prolonged stimulation would not explain equal proportions since this would have led to higher proportions of T cells specific for immunodominant antigens in the 7-day assay.Analyses of IFNγ in supernatants by ELISA at day 7 following two rounds of restimulation revealed a similar tendency for PPD, immunodominant, and latency-associated M. tuberculosis proteins in LTBI (figure 2A). In contrast to intracellular staining, a considerable amount of IFNγ was also detected in supernatants of PBMC from some TST-negative donors after stimulation with latency-associated antigens (figure 2B). Therefore intracellular measurement of IFNγ after two rounds of in vitro restimulation revealed higher specificity as compared to the IFNγ ELISA.
Figure 2
IFNγ ELISA analyses after restimulation with immunodominant and latency-associated antigens of PBMC from LTBI and TST-negative donors.
Analyses of IFNγ in the culture supernatant by ELISA after 7 days and two rounds of in vitro restimulation in PBMC from LTBI (A) and TST-negative donors (B) are shown. Scatter plots indicate mean and standard deviation. Background values of non-stimulated controls were subtracted. IFNγ concentrations in the supernatant are indicated on the y-axis for stimulation with SEB, PPD from M. tuberculosis, and tested antigens (x-axes). The most promising candidate Rv3407 is underlined.
IFNγ ELISA analyses after restimulation with immunodominant and latency-associated antigens of PBMC from LTBI and TST-negative donors.
Analyses of IFNγ in the culture supernatant by ELISA after 7 days and two rounds of in vitro restimulation in PBMC from LTBI (A) and TST-negative donors (B) are shown. Scatter plots indicate mean and standard deviation. Background values of non-stimulated controls were subtracted. IFNγ concentrations in the supernatant are indicated on the y-axis for stimulation with SEB, PPD from M. tuberculosis, and tested antigens (x-axes). The most promising candidate Rv3407 is underlined.
Significantly stronger T-cell responses in LTBI as compared to TB patients against latency-associated antigens
The expression of the vast majority of antigens used in this study has been associated with latent stages of M. tuberculosis infection. Consequently, we addressed the question whether these antigens are differentially recognized by T cells from patients with active pulmonary TB and LTBI. Eleven latency-associated antigens (i.e. Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c, and Rv3407), which induced strong responses in LTBI, were selected for these experiments. Seven of these latency-associated antigens induced significantly higher T-cell responses in LTBI as compared to TBpatients (P<0.001 for Rv1733c, Rv2003, Rv2005c, Rv0140, and Rv3407; P<0.01 for Rv1009; P<0.05 for Rv2450c) (figure 3A).
Figure 3
Comparison of IFNγ-expressing CD4+ T cells specific for immunodominant and latency-associated M. tuberculosis antigens between patients with TB, LTBI, and TST-negative donors.
(A). Percentages of IFNγ-expressing CD4+ CD45RO+ memory T cells are shown for stimulation with SEB, PPD from M. tuberculosis, and 11 latency-associated antigens after 7 days and two rounds of in vitro restimulation. T-cell responses from TST-negative donors are indicated as green circles, LTBI are indicated as blue squares, and TB patients are indicated as red triangles. Two-sided p-values for the Mann-Whitney U-test are indicated as follows: * P<0.05, ** P<0.01; and *** P<0.001. (B) Classification of TB patients and LTBI based on random forest analysis using 11 latency-associated antigens as well as ESAT6_CFP-10, and PPD. Results from the cross validation are shown in a bar chart. Each bar represents an individual donor. TB patients are shown on the left (red bars), LTBI on the right side (blue bars). The y-axis indicates the prediction threshold calculated by random forest analysis. Negative bars predict a TB patient, positive bars an LTBI. The prediction probability is represented as the bar height. (C) Mean decrease of class impurity over all trees measured as Gini index (y-axis) indicates the relative importance of each factor (x-axis) for classification. PPD: purified protein derivative of M. tuberculosis; SEB Staphylococcus enterotoxin B.
Comparison of IFNγ-expressing CD4+ T cells specific for immunodominant and latency-associated M. tuberculosis antigens between patients with TB, LTBI, and TST-negative donors.
(A). Percentages of IFNγ-expressing CD4+ CD45RO+ memory T cells are shown for stimulation with SEB, PPD from M. tuberculosis, and 11 latency-associated antigens after 7 days and two rounds of in vitro restimulation. T-cell responses from TST-negative donors are indicated as green circles, LTBI are indicated as blue squares, and TBpatients are indicated as red triangles. Two-sided p-values for the Mann-Whitney U-test are indicated as follows: * P<0.05, ** P<0.01; and *** P<0.001. (B) Classification of TBpatients and LTBI based on random forest analysis using 11 latency-associated antigens as well as ESAT6_CFP-10, and PPD. Results from the cross validation are shown in a bar chart. Each bar represents an individual donor. TBpatients are shown on the left (red bars), LTBI on the right side (blue bars). The y-axis indicates the prediction threshold calculated by random forest analysis. Negative bars predict a TBpatient, positive bars an LTBI. The prediction probability is represented as the bar height. (C) Mean decrease of class impurity over all trees measured as Gini index (y-axis) indicates the relative importance of each factor (x-axis) for classification. PPD: purified protein derivative of M. tuberculosis; SEB Staphylococcus enterotoxin B.We set a threshold of 0.2% IFNγ+, CD4+, CD45RO+ T cells (i.e. 20-fold above the assumed flow cytometric detection threshold of 0.01%) to define positive T-cell responses against latency-associated antigens in LTBI and TBpatients for the most promising candidates (P<0.001) (Table 2). Latency-associated antigens induced T-cell responses in the range of 45.5 to 72.7% of LTBI patients. A specific T-cell response against Rv2003 was detected in the vast majority of LTBI (16 of 22) but also induced positive responses in 25% (5 of 20) of the TBpatients. Notably, the resuscitation-associated antigen Rv3407 [19] induced positive T-cell responses in 12 LTBI (55%) but in none of the TBpatients. These results prompted us to determine whether T-cell responses against M. tuberculosis antigens are sufficient for classification of TBpatients and LTBI.
Table 2
Positive T-cell responses against latency-associated antigens.
Antigen
LTBI1(%)
TB patients1(%)
Rv2003
16 (72.7)
5 (25)
Rv1733c
15 (68.2)
2 (10)
Rv3407
12 (54.5)
0 (0)
Rv2005c
12 (54.5)
3 (15)
Rv0140
10 (45.5)
2 (10)
Number of donors with more than 0.2% IFNγ-producing T cells.
Number of donors with more than 0.2% IFNγ-producing T cells.
T-cell responses against latency-associated antigens discriminate between LTBI and TB patients
We included the 11 immunogenic latency-associated antigens together with ESAT6_CFP-10, and PPD in a discrimination approach. Random forest analyses together with leave-1-out cross-validations across all possible combinations were applied to determine the prediction accuracy and relative importance of each factor for classification. These analyses revealed a cross-validated prediction accuracy of 83% between TBpatients and LTBI (figure 3B). The relative feature importance for discrimination showed that Rv3407 was by far the most influential factor for classification (figure 3C). Consequently we designed overlapping peptide pools of Rv3407 to identify immunogenic epitopes.
Identification of immunogenic peptides of Rv3407
The matrix design of the overlapping peptide pools leads to six ‘vertical’ and five ‘horizontal’ pools. Each of the 29 peptides of Rv3407 was present in two pools (Table 3). In 6 out of 10 LTBI tested – those with the highest T-cell response against Rv3407 – a minimum of 0.2% IFNγ-expressing CD4+ T cells was detected after stimulation with at least two of the peptide pools (figure 4). In four LTBI (LTBI-A to LTBI-D) a major immunogenic epitope could be identified (figure 4A–D) while in two LTBI (LTBI-E, LTBI-F) with the weakest response against the Rv3407 protein no prominent epitope-specific T-cell responses were observed (figure 4E–F). Notably peptide 6 (LRQHASRYLARVEAG) identified in LTBI-A induced IFNγ expression in about 1% of CD8+ memory T cells, as well (data not shown). Therefore distinct peptide epitopes in different LTBI were recognized by antigen-specific T cells and ongoing studies will determine whether this is due to differential HLA-phenotypes.
Table 3
Design of Rv3407 peptide pools.
No.1
Amino acid sequence
P1
MRATVGLVEAIGIRE
P2
TVGLVEAIGIRELRQ
P3
LVEAIGIRELRQHAS
P4
AIGIRELRQHASRYL
P5
IRELRQHASRYLARV
P6
LRQHASRYLARVEAG
P7
HASRYLARVEAGEEL
P8
RYLARVEAGEELGVT
P9
ARVEAGEELGVTNKG
P10
EAGEELGVTNKGRLV
P11
EELGVTNKGRLVARL
P12
GVTNKGRLVARLIPV
P13
NKGRLVARLIPVQAA
P14
RLVARLIPVQAAERS
P15
ARLIPVQAAERSREA
P16
IPVQAAERSREALIE
P17
QAAERSREALIESGV
P18
ERSREALIESGVLIP
P19
REALIESGVLIPARR
P20
LIESGVLIPARRPQN
P21
SGVLIPARRPQNLLD
P22
LIPARRPQNLLDVTA
P23
ARRPQNLLDVTAEPA
P24
PQNLLDVTAEPARGR
P25
LLDVTAEPARGRKRT
P26
VTAEPARGRKRTLSD
P27
EPARGRKRTLSDVLN
P28
RGRKRTLSDVLNEMR
P29
KRTLSDVLNEMRDEQ
Peptide number according to the position within the primary sequence from C- to N-terminus.
Figure 4
Overlapping peptide pools of latency-associated protein Rv3407 stimulate IFNγ-expressing CD4+ T cells after 7 days and two rounds of restimulation.
PBMC from six LTBI (A–F) were restimulated with 15-mer synthetic peptide pools of Rv3407 for 7 days including two rounds of in vitro restimulation. IFNγ-expressing CD4+ CD45RO+ T cells are shown for stimulation with peptide pools 1 to 6 (grey bars) and pools 7 to 11 (black bars). Each peptide is constituent of one pool within pools 1 to 6 and of one pool within pools 7 to 11. Peptides inducing the most prominent responses are indicated for donors A–D. The horizontal line indicates the threshold for positive responses (0.2%). Background values of non-stimulated controls were subtracted.
Overlapping peptide pools of latency-associated protein Rv3407 stimulate IFNγ-expressing CD4+ T cells after 7 days and two rounds of restimulation.
PBMC from six LTBI (A–F) were restimulated with 15-mer synthetic peptide pools of Rv3407 for 7 days including two rounds of in vitro restimulation. IFNγ-expressing CD4+ CD45RO+ T cells are shown for stimulation with peptide pools 1 to 6 (grey bars) and pools 7 to 11 (black bars). Each peptide is constituent of one pool within pools 1 to 6 and of one pool within pools 7 to 11. Peptides inducing the most prominent responses are indicated for donors A–D. The horizontal line indicates the threshold for positive responses (0.2%). Background values of non-stimulated controls were subtracted.Peptide number according to the position within the primary sequence from C- to N-terminus.We consider the detection of specific T-cell immunity against latency-associated antigens and the identification of immunogenic epitopes an initial step towards definition of reliable biomarkers for protective immunity against TB.
The clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. All donors gave written informed consent and the local ethics committee of the University Hospital Berlin at Charité approved this study (205-18.1; 205-18.2; 205-18.3).
Human subjects
Peripheral blood (40 ml) was obtained from 22 LTBI and 20 patients with active pulmonary TB. LTBI and TBpatients were recruited at HELIOS clinic Emil-von-Behring and the Charité, both in Berlin; and at the Asklepios Clinic, Munich-Gauting. Diagnosis of LTBI was based on positive TST (>10 mm) and positive T-Spot TB™. TB diagnosis was based on patient history, chest X-ray, TST, and mycobacterial culture. Ten M. tuberculosis non-infected (TST-negative) donors were recruited among volunteers of the Max Planck Institute for Infection Biology, Berlin. All donors were Caucasians. There was no gender bias and only minor age differences between both study groups (Table 4).
Table 4
Characteristics of LTBI, TB patients and non-infected donors.
LTBI1
TB patients2
Non-infected donors3
Total number
22
20
10
Female
11
10
5
Male
11
10
5
Age range years (median)
28–64 (47)
26–63 (41)
24–55 (36)
healthy latently M. tuberculosis-infected donors.
patients with active pulmonary TB.
healthy tuberculin skin test (TST)-negative donors.
healthy latently M. tuberculosis-infected donors.patients with active pulmonary TB.healthy tuberculin skin test (TST)-negative donors.
Recombinant M. tuberculosis proteins and synthetic peptide pools
Recombinant M. tuberculosis proteins (Table 1) were expressed in Escherichia coli and purified as described previously [5], [27]. Synthetic 15-mer peptide pools representing Rv3407 were generated with an overlap of 12 amino acids using combinatory chemistry (Jerini). The pools were designed as matrix pools as described before [28]. The peptides are listed in Table 3.
Cell culture assays
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation (Biocoll, Biochrom) following manufacturer's instructions and 2×105 cells were cultured in 200 µL medium A [(RPMI-1640 (GIBCO, Invitrogen) with 10% human serum (Sigma-Aldrich), 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM L-glutamine and 10 mM HEPES (all PAA laboratories)] using 96-well round-bottom plates (NUNC). Each well was surrounded by wells filled with sterile water (200 µl) to avoid drying effects. In the short-term assay we stimulated PBMC for 16 h with different recombinant M. tuberculosis proteins (5 µg/ml, see Table 1), purified protein derivative (PPD) of M. tuberculosis (5 µg/ml) (Statens Serum Institute), Staphylococcus enterotoxin B (SEB) (1 µg/ml) (Sigma-Aldrich), and synthetic peptide pools (5 µg/ml per peptide) at 37°C and 5% CO2. After 4 h of incubation brefeldin A (10 µg/ml) (Sigma-Aldrich) was added.In the long-term assay the same stimuli were applied at the beginning except for SEB that was added on day 6 to a well of non-stimulated cultured cells. For each of the other stimuli the same antigen was added on day 6 in 20 µl medium A using the same final concentrations. In the long-term assay, brefeldin A (10 µg/ml) was added 4 h after the second restimulation only, and cells were then cultured for an additional 12 h.Afterwards, for both assays, cells were fixed and permeabilized using cytofix/cytoperm™ (BD Biosciences) following manufacturer's instructions and stained with the following fluorochrome-labeled monoclonal antibodies: α-CD3 (Pacific Blue) (BioLegend), α-CD4 (APC-Cy7), α-CD8 (PerCP), α-CD45RO (Pe-Cy7), α-IFNγ (APC) (all BD Biosciences). After staining for 45 min at 4°C, cells were washed twice in cytoperm/wash, and once in PBS containing 10% FCS. Measurements and analyses were performed using a LSRII flow cytometer and FACS-Diva software (both BD Biosciences). Examples of the procedures of analysis are shown in Figure 5A for a TBpatient and Figure 5B for an LTBI. About 18000 CD4+ CD45RO+ T cells were collected for each sample. For background determinations, values of non-stimulated controls were subtracted from the different stimuli of each individual donor.
Figure 5
Gating procedures of flow cytometry analyses to determine protein candidate specific T cell proportions.
Representative analyses from a patient with Tb (A) and an LTBI (B) are shown. Open red circles and dot plot connected by red arrows indicate the sequence of analysis steps. First, lymphocytes were gated using size (forward scatter; FSC) and granularity (side scatter, SSC). These cells were then analyzed for CD4 expression. CD4+ T cells were analyzed for IFNγ CD45RO expression for each stimulation (without stimulus, w/o; proteine 3; protein 11; SEB). Proportions of CD45ROhigh IFNγ expressing CD4+ T cells (upper right quadrants) were determined. The background of non-stimulated T cells (w/o) was subtracted for analyses.
Gating procedures of flow cytometry analyses to determine protein candidate specific T cell proportions.
Representative analyses from a patient with Tb (A) and an LTBI (B) are shown. Open red circles and dot plot connected by red arrows indicate the sequence of analysis steps. First, lymphocytes were gated using size (forward scatter; FSC) and granularity (side scatter, SSC). These cells were then analyzed for CD4 expression. CD4+ T cells were analyzed for IFNγ CD45RO expression for each stimulation (without stimulus, w/o; proteine 3; protein 11; SEB). Proportions of CD45ROhigh IFNγ expressing CD4+ T cells (upper right quadrants) were determined. The background of non-stimulated T cells (w/o) was subtracted for analyses.
Cytokine analyses in culture supernatants by ELISA
PBMC (5×104) were added to 96-well round-bottom plates (NUNC) in 200 µL medium. Cells were stimulated for 7 days as described in the previous section but without adding brefeldin A. We harvested 110 µl of cell culture supernatant at day 7. The IFNγ ELISA (BD Biosciences) was performed according to manufacturer's guidelines. Plates were analyzed by measuring extinction at 450 nm using an ELISA plate reader (Molecular Devices).
Donor classification and significance analyses
The discriminatory power for classifying TBpatients and LTBI was investigated using random forest analysis [29] based on the proportion of IFNγ-expressing CD4+, CD45RO+ T cells against 13 selected stimuli (i.e. PPD, ESAT6_CFP10, Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c, and Rv3407). We determined the relative feature importance for discrimination using a leave-1-out cross validation for all possible combinations of genes and assessed the proportion of correctly classified patients in the left-out group.For significance analyses the Mann-Whitney U-test was used. Significance of two-sided p-values is indicated as follows: * P<0.05, ** P<0.01, and *** P<0.001.
Authors: H T Maecker; H S Dunn; M A Suni; E Khatamzas; C J Pitcher; T Bunde; N Persaud; W Trigona; T M Fu; E Sinclair; B M Bredt; J M McCune; V C Maino; F Kern; L J Picker Journal: J Immunol Methods Date: 2001-09-01 Impact factor: 2.303
Authors: Tom H M Ottenhoff; Frank A W Verreck; Elgin G R Lichtenauer-Kaligis; Marieke A Hoeve; Ozden Sanal; Jaap T van Dissel Journal: Nat Genet Date: 2002-09 Impact factor: 38.330
Authors: K L Franken; H S Hiemstra; K E van Meijgaarden; Y Subronto; J den Hartigh; T H Ottenhoff; J W Drijfhout Journal: Protein Expr Purif Date: 2000-02 Impact factor: 1.650
Authors: J Mattow; P R Jungblut; U E Schaible; H J Mollenkopf; S Lamer; U Zimny-Arndt; K Hagens; E C Müller; S H Kaufmann Journal: Electrophoresis Date: 2001-08 Impact factor: 3.535
Authors: S Biketov; G V Mukamolova; V Potapov; E Gilenkov; G Vostroknutova; D B Kell; M Young; A S Kaprelyants Journal: FEMS Immunol Med Microbiol Date: 2000-12
Authors: Hans-Willi Mittrücker; Ulrich Steinhoff; Anne Köhler; Marion Krause; Doris Lazar; Peggy Mex; Delia Miekley; Stefan H E Kaufmann Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: Uma Shanmugasundaram; Allison N Bucsan; Shashank R Ganatra; Chris Ibegbu; Melanie Quezada; Robert V Blair; Xavier Alvarez; Vijayakumar Velu; Deepak Kaushal; Jyothi Rengarajan Journal: JCI Insight Date: 2020-07-23
Authors: Chelsea Carpenter; John Sidney; Ravi Kolla; Kaustuv Nayak; Helena Tomiyama; Claudia Tomiyama; Oscar A Padilla; Virginie Rozot; Syed F Ahamed; Carlos Ponte; Valeria Rolla; Paulo R Antas; Anmol Chandele; John Kenneth; Seetha Laxmi; Edward Makgotlho; Valentina Vanini; Giuseppe Ippolito; Alexandra S Kazanova; Alexander V Panteleev; Willem Hanekom; Harriet Mayanja-Kizza; David Lewinsohn; Mayuko Saito; M Juliana McElrath; W Henry Boom; Delia Goletti; Robert Gilman; Irina V Lyadova; Thomas J Scriba; Esper G Kallas; Kaja Murali-Krishna; Alessandro Sette; Cecilia S Lindestam Arlehamn Journal: Tuberculosis (Edinb) Date: 2015-08-01 Impact factor: 3.131
Authors: Lerisa Govender; Brian Abel; E Jane Hughes; Thomas J Scriba; Benjamin M N Kagina; Marwou de Kock; Gerhard Walzl; Gillian Black; Ida Rosenkrands; Gregory D Hussey; Hassan Mahomed; Peter Andersen; Willem A Hanekom Journal: Vaccine Date: 2010-10-23 Impact factor: 3.641
Authors: K F Siddiqui; M Amir; N Khan; G Rama Krishna; J A Sheikh; K Rajagopal; J N Agrewala Journal: Clin Exp Immunol Date: 2015-06-03 Impact factor: 4.330
Authors: Heidi A Schreiber; Jeffrey S Harding; Oliver Hunt; Christopher J Altamirano; Paul D Hulseberg; Danielle Stewart; Zsuzsanna Fabry; Matyas Sandor Journal: J Clin Invest Date: 2011-09-12 Impact factor: 14.808
Authors: Rachel L Leistikow; Russell A Morton; Iona L Bartek; Isaac Frimpong; Karleen Wagner; Martin I Voskuil Journal: J Bacteriol Date: 2009-12-18 Impact factor: 3.490
Authors: Tony W Ng; Noemí A Saavedra-Ávila; Steven C Kennedy; Leandro J Carreño; Steven A Porcelli Journal: Expert Rev Vaccines Date: 2015-09-14 Impact factor: 5.217